SCHEMBL1362524

SCHEMBL1362524

Brc1ccc2c(-c3ccccc3)n[nH]c2c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.75
DYRK1A Q13627 2/20 0.75
DCLK1 O15075 1/20 0.75
PRKD3 O94806 1/20 0.75
MAP4K4 O95819 1/20 0.75
CHEK2 O96017 1/20 0.75
CSF1R P07333 1/20 0.75
FER P16591 1/20 0.75
MARK3 P27448 1/20 0.75
FLT4 P35916 1/20 0.75
FLT3 P36888 1/20 0.75
MAPK9 P45984 1/20 0.75
CSNK1D P48730 1/20 0.75
CLK2 P49760 1/20 0.75
CSNK2A1 P68400 1/20 0.75
CSNK1G2 P78368 1/20 0.75
MAP4K2 Q12851 1/20 0.75
STK3 Q13188 1/20 0.75
CAMK2B Q13554 1/20 0.75
CAMK2G Q13555 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31210155 0.97 CDK2 (0.71) CDK2DYRK1ADCLK1PRKD3MAP4K4
SCHEMBL4316858 0.86 DCLK1 (1.00) CDK2DYRK1ADCLK1PRKD3MAP4K4
SCHEMBL10112175 0.84 DYRK1A (0.58) CDK2DYRK1ADCLK1PRKD3MAP4K4
SCHEMBL11686272 0.83 DCLK1 (0.71) CDK2DYRK1ADCLK1PRKD3MAP4K4
SCHEMBL29549117 0.83 MAP2K4 (0.61) CDK2DYRK1ADCLK1PRKD3MAP4K4
SCHEMBL4215112 0.83 MAP2K4 (0.61) CDK2DYRK1ADCLK1PRKD3MAP4K4
SCHEMBL1513016 0.81 FGFR1 (0.71) CDK2DYRK1ADCLK1PRKD3MAP4K4
SCHEMBL4219256 0.79 PDPK1 (0.54) CDK2DYRK1ADCLK1PRKD3MAP4K4
SCHEMBL4217257 0.79 AXL (0.58) CDK2DYRK1ADCLK1PRKD3MAP4K4
SCHEMBL4224562 0.79 LRRK2 (0.67) CDK2DYRK1ADCLK1PRKD3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117247392-A Carbazolophenazinyl-containing compound, intermediate for preparing carbazolophenazinyl-containing compound and application of carbazolophenazinyl-containing compound 阜阳欣奕华材料科技有限公司 2023-12-19 CN disclosed
US-8067447-B2 Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2011-11-29 US disclosed
US-20100076014-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076014-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF NFRKB, NFKBIA, NFKB1 CDK2 3203/4885DYRK1A 1878/4885DCLK1 1708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.